Skip to main content

Part of the book series: UICC International Union Against Cancer ((UICCI))

  • 131 Accesses

Abstract

In many respects, the development of systemic therapies for cancer has paralleled the development of antimicrobial therapy. The challenges and controversies that the pioneers in the development of systemic agents for the treatment of cancer met were similar to those the developers of antimicrobials encountered. For example, medical students in the 1920s were taught the reasons why “... any form of antibacterial chemotherapy...” was “... an impossible dream.” Respected medical researchers in the 1940s likened the challenge of finding an effective anticancer drug to the problem of finding an agent that would dissolve the left ear but leave the right ear unharmed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Further Reading

  • Coleman CN, Bump EA, Kramer RA (1988) Chemical modifiers of cancer treatment. Journal of Clinical Oncology 6: 709–733

    CAS  PubMed  Google Scholar 

  • Collins 3M (1984) Pharmacokinetic rationale for regional drug delivery. Journal of Clinical Oncology 2: 498–504

    Google Scholar 

  • DeVita VT, Jr., Hellman S, Rosenberg SA (eds) (1985) Principles of chemotherapy. In: Cancer–principles and practice of oncology, 2nd edn. Lippincott, Philadelphia, pp 257–285

    Google Scholar 

  • Goldie JH (1987) Scientific bases for adjuvant and primary (neoadjuvant) chemotherapy. Seminars in Oncology 14: 1–7

    CAS  PubMed  Google Scholar 

  • Goldie JH, Coleman AJ (1984) The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Research 44: 3643–3653

    CAS  PubMed  Google Scholar 

  • Hryniuk W, Bush H (1984) The importance of dose density in chemotherapy of metastatic breast cancer. Journal of Clinical Oncology 2: 1281–1288

    CAS  PubMed  Google Scholar 

  • Moscan JA, Cowan KH (1988) Multi-drug resistance. Journal of the National Cancer Institute 80: 14–20

    Article  Google Scholar 

  • Schabel FM (1977) Rationale for adjuvant chemotherapy. Cancer 39:2875–2882

    Article  CAS  PubMed  Google Scholar 

  • Schnipper LE (1986) Clinical implications of tumor cell heterogeneity. New England Journal of Medicine 314: 1423–1431

    Article  CAS  PubMed  Google Scholar 

  • Weber G (1983) The biochemical strategy of cancer cells and the design of chemotherapy. Cancer Research 43: 3466–3492

    CAS  PubMed  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Trump, D.L., Smith, D.C. (1994). Systemic Therapies. In: Love, R.R. (eds) Manual of Clinical Oncology. UICC International Union Against Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-85159-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85159-9_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-58193-2

  • Online ISBN: 978-3-642-85159-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics